“The combination of reduced cost, enhanced beam precision, and greater flexibility to incorporate technological improvements creates significant advantages to proton vendors and hospital users,” says P-Cure CEO Michael Marash.
New York (PRWEB) November 26, 2012
P-Cure Ltd has begun assembly of its first clinical platform which, when installed in an operating center, will demonstrate significant reduction in the capital costs of proton centers. To accommodate both manufacturing as well as on-going development, P-Cure has moved into a new office and assembly center in Lod, outside of Tel Aviv.
The first commercial installation of the P-Cure image-guided positioning and Adaptive Therapy solutions system will be installed in the ProCure Metro New York/New Jersey Proton Cancer Treatment Center. The mission of P-Cure is to both increase the precision of proton therapy as well as to reduce the capital costs of proton centers so as to expand patient access.
“If cost was not an issue, proton therapy would be the default radiation system for treating most sites of non-metastasized cancer. Proton therapy is physically more accurate, thereby resulting in less treatment related side effects. It is indicated for tumors requiring high doses of radiation situated close to critical organs such as the central nervous system. Protons may be the best treatment alternative for children with any form of cancer, and in adult cancers proton therapy is being investigated in patients with prostate cancer, breast cancer and lung cancers" says Dr. Raphael Pfeffer, MD, Chief of the Oncology Department at the Assuta Medical Center.
With significantly reduced equipment and building costs, proton therapy has the potential to replace most forms of x-ray treatments based on its proven ability to reduce harmful radiation to healthy tissues and organs.
P-Cure is demonstrating that the capital cost of expandable one room centers, as well as the more typical multi-room center, can be significantly reduced. P-Cure projects that a 3 or 4 room center, including building and equipment from existing vendors, could be patient-ready at one-third of current costs.
“With the P-Cure system and using any vendors’ cyclotron or synchrotron, our solution is easily expandable at significant cost savings, and incorporates our proprietary Adaptive Therapy solution for more accurate beam delivery to the changing shape of the tumor. This makes even single room centers adaptable and versatile to changing needs, expanded treatment protocols, and increased patient needs,” says P-Cure CEO Michael Marash. “Current centers require 100 to 200 ton gantries in their full service treatment rooms to bend the beam to the patient’s tumor site. With the P-Cure solution, instead of bending the beam to the patient, we can more accurately position the patient in front of a fixed beam in either a seated or laying position.”
Reduction in capital cost both makes proton centers more economically viable and promises greater access to patients who can benefit from proton therapy. Because of the high capital costs, proton therapy is available to less than one percent of those patients who could benefit from it. The use of proton beams enables radiation oncologists to deliver higher radiation doses to neutralize cancers while sparing surrounding normal organs and tissues. Proton therapy is minimally invasive; recovery is enhanced and patients retain a high quality of life after recovery.
“The P-Cure comprehensive solution to capital cost reduction, and reduced operating costs, is only part of our value to hospitals and proton developers,” says Marash. “Incorporating our system into a proposed proton center allows maximum flexibility as the technology develops. Our system is expandable, compatible to scanning protocols, and includes Adaptive Therapy for accurate beam placement on the fly. The combination of reduced cost, enhanced beam precision, and greater flexibility to incorporate technological improvements creates significant advantages to proton vendors and hospital users.”
P-Cure, an innovative high tech company, develops and manufactures solutions for more effective delivery of proton therapy at a fraction of the current capital and operating costs. The P-Cure solution is an accelerator-complementary image-guided positioning and treatment adaptation solution. Combined with a beam delivery system of its partners the P-Cure integrated solution is capable of supporting the entire proton treatment course for both scanning and scattering configurations. The first product of P-Cure, the P-Art patient positioning software, was cleared by the FDA in 2010. The P-Cure solution is compatible with all vendors, developers and turnkey offerings. [http://www.p-cure.com